{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:07:50Z","timestamp":1788314870059,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008982","name":"Qatar National Research Fund","doi-asserted-by":"publisher","award":["NPRP6-065-3-012"],"award-info":[{"award-number":["NPRP6-065-3-012"]}],"id":[{"id":"10.13039\/100008982","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.ejps.2018.10.014","type":"journal-article","created":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T02:08:10Z","timestamp":1540001290000},"page":"79-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Production of \u201cbiobetter\u201d glucarpidase variants to improve drug detoxification and antibody directed enzyme prodrug therapy for cancer treatment"],"prefix":"10.1016","volume":"127","author":[{"given":"Alanod D.","family":"AlQahtani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layla","family":"Al-mansoori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara S.","family":"Bashraheel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma B.","family":"Rashidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afrah","family":"Al-Yafei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Elsinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Domling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayed K.","family":"Goda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ejps.2018.10.014_bb0005","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/nbt1007-1097","article-title":"What's fueling the biotech engine?","volume":"25","author":"Aggarwal","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejps.2018.10.014_bb0010","series-title":"Tumor Targeting","first-page":"17","article-title":"Antibody-directed enzyme prodrug therapy: a pilot clinical trial","volume":"1","author":"Bagsgawe","year":"1995"},{"issue":"6","key":"10.1016\/j.ejps.2018.10.014_bb0015","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/bjc.1988.293","article-title":"A cytotoxic agent can be generated selectively at cancer sites","volume":"58","author":"Bagshawe","year":"1988","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejps.2018.10.014_bb0020","series-title":"Current Opinion in Investigational Drugs (London, England: 2000)","first-page":"1530","volume":"2(11)","author":"Barnard","year":"2001"},{"issue":"11","key":"10.1016\/j.ejps.2018.10.014_bb0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050028","article-title":"PEGylation extends circulation half-life while preserving in vitro and in vivo activity of tissue inhibitor of metalloproteinases-1 (TIMP-1)","volume":"7","author":"Batra","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ejps.2018.10.014_bb0030","doi-asserted-by":"crossref","first-page":"18041","DOI":"10.1038\/s41598-017-18029-y","article-title":"Generation of therapeutic protein variants with the human serum albumin binding capacity via site-specific fatty acid conjugation","volume":"7","author":"Cho","year":"2017","journal-title":"Sci. Rep."},{"issue":"16","key":"10.1016\/j.ejps.2018.10.014_bb0035","doi-asserted-by":"crossref","first-page":"9443","DOI":"10.1074\/jbc.273.16.9443","article-title":"Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes","volume":"273","author":"Davidson","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"9\u201310","key":"10.1016\/j.ejps.2018.10.014_bb0040","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s10930-009-9211-2","article-title":"Functional overexpression and purification of a codon optimized synthetic glucarpidase (carboxypeptidase G2) in Escherichia coli","volume":"28","author":"Goda","year":"2009","journal-title":"Protein J."},{"issue":"10","key":"10.1016\/j.ejps.2018.10.014_bb0045","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1634\/theoncologist.2012-0123","article-title":"U.S. Food and Drug Administration approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma","volume":"17","author":"Herndon","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.ejps.2018.10.014_bb0050","series-title":"Enzymes as Drugs","first-page":"77","article-title":"Folate-degrading enzymes: a review with special emphasis on carboxypeptidase G","author":"Kalghatgi","year":"1981"},{"key":"10.1016\/j.ejps.2018.10.014_bb0055","series-title":"Methods for General and Molecular Bacteriology","author":"Kamlage","year":"1994"},{"issue":"12","key":"10.1016\/j.ejps.2018.10.014_bb0060","doi-asserted-by":"crossref","first-page":"606","DOI":"10.5483\/BMBRep.2013.46.12.106","article-title":"Novel AGLP-1 albumin fusion protein as a long-lasting agent for type 2 diabetes","volume":"46","author":"Kim","year":"2013","journal-title":"BMB Rep."},{"issue":"6","key":"10.1016\/j.ejps.2018.10.014_bb0065","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.copbio.2011.06.012","article-title":"Strategies for extended serum half-life of protein therapeutics","volume":"22","author":"Kontermann","year":"2011","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.ejps.2018.10.014_bb0070","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cbpa.2016.08.006","article-title":"How PEGylation influences protein conformational stability","volume":"34","author":"Lawrence","year":"2016","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejps.2018.10.014_bb0075","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jconrel.2015.04.004","article-title":"Site-specific albumination of a therapeutic protein with multi-subunit to prolong activity in vivo","volume":"207","author":"Lim","year":"2015","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.ejps.2018.10.014_bb0080","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s002800050646","article-title":"Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial","volume":"40","author":"Martin","year":"1997","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"22","key":"10.1016\/j.ejps.2018.10.014_bb0085","doi-asserted-by":"crossref","first-page":"6741","DOI":"10.1111\/j.1742-4658.2009.07387.x","article-title":"Site-directed enzymatic PEGylation of the human granulocyte colony-stimulating factor","volume":"276","author":"Maullu","year":"2009","journal-title":"FEBS J."},{"issue":"6","key":"10.1016\/j.ejps.2018.10.014_bb0090","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00262-004-0624-7","article-title":"Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin\u20112\u2011human serum albumin fusion protein in mice","volume":"54","author":"Melder","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"issue":"3","key":"10.1016\/j.ejps.2018.10.014_bb0095","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1128\/jb.156.3.1222-1227.1983","article-title":"Molecular cloning of the Pseudomonas carboxypeptidase G2 gene and its expression in Escherichia coli and Pseudomonas putida","volume":"156","author":"Minton","year":"1983","journal-title":"J. Bacteriol."},{"issue":"17","key":"10.1016\/j.ejps.2018.10.014_bb0100","doi-asserted-by":"crossref","first-page":"12650","DOI":"10.1074\/jbc.M700820200","article-title":"Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin","volume":"282","author":"Muller","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejps.2018.10.014_bb0105","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0065-3233(08)60065-0","article-title":"Serum albumin","volume":"37","author":"Peters","year":"1985","journal-title":"Adv. Protein Chem."},{"issue":"2","key":"10.1016\/j.ejps.2018.10.014_bb0110","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1099\/00221287-85-2-283","article-title":"Bacterial degradation of folic acid","volume":"85","author":"Rappold","year":"1974","journal-title":"J. Gen. Microbiol."},{"issue":"4","key":"10.1016\/j.ejps.2018.10.014_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196254","article-title":"Isolation and molecular characterization of novel glucarpidases: enzymes to improve the antibody directed enzyme pro-drug therapy for cancer treatment","volume":"13","author":"Rashidi","year":"2018","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ejps.2018.10.014_bb0120","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/cphc.201000815","article-title":"Direct evidence of coexisting horseshoe and extended helix conformations of membrane-bound alpha-synuclein","volume":"12","author":"Robotta","year":"2011","journal-title":"Chemphyschem"},{"issue":"17","key":"10.1016\/j.ejps.2018.10.014_bb0125","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1007\/s00253-016-7447-2","article-title":"Expression and bioactivity of recombinant human serum albumin and dTMP fusion proteins in CHO cells","volume":"100","author":"Ru","year":"2016","journal-title":"Appl. Microbiol. Biotechnol."},{"issue":"12","key":"10.1016\/j.ejps.2018.10.014_bb0130","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/nbt.1588","article-title":"A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner","volume":"27","author":"Schellenberger","year":"2009","journal-title":"Nat. Biotechnol."},{"issue":"2 Pt 1","key":"10.1016\/j.ejps.2018.10.014_bb0135","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1158\/1078-0432.814.11.2","article-title":"Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy","volume":"11","author":"Sharma","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.ejps.2018.10.014_bb0140","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1432-1033.1985.tb08860.x","article-title":"Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16. Use of a novel triazine dye affinity method","volume":"148","author":"Sherwood","year":"1985","journal-title":"Eur. J. Biochem."},{"issue":"22","key":"10.1016\/j.ejps.2018.10.014_bb0145","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1093\/nar\/22.22.4673","article-title":"CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice","volume":"22","author":"Thompson","year":"1994","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.ejps.2018.10.014_bb0150","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.pep.2013.05.002","article-title":"Construction and characterization of a potent, long-lasting recombinant human serum albumin-interferon alpha1 fusion protein expressed in Pichia pastoris","volume":"90","author":"Tian","year":"2013","journal-title":"Protein Expr. Purif."},{"issue":"4","key":"10.1016\/j.ejps.2018.10.014_bb0155","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00726-005-0289-3","article-title":"Strategies to improve plasma half life time of peptide and protein drugs","volume":"30","author":"Werle","year":"2006","journal-title":"Amino Acids"},{"issue":"2","key":"10.1016\/j.ejps.2018.10.014_bb0160","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ejpb.2009.01.008","article-title":"Elimination of the free sulfhydryl group in the human serum albumin (HSA) moiety of human interferon-alpha2b and HSA fusion protein increases its stability against mechanical and thermal stresses","volume":"72","author":"Zhao","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098718304615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098718304615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:47:11Z","timestamp":1760528831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098718304615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":32,"alternative-id":["S0928098718304615"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2018.10.014","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Production of \u201cbiobetter\u201d glucarpidase variants to improve drug detoxification and antibody directed enzyme prodrug therapy for cancer treatment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2018.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}